Cargando…
Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease
BACKGROUND: Thiopurines remain recommended as maintenance therapy in patients with inflammatory bowel disease (IBD). Despite their widespread use, long‐term effectiveness data are sparse and safety is an increasingly debated topic which thwarts proper delineation in the current IBD treatment algorit...
Autores principales: | Rezazadeh Ardabili, Ashkan, Jeuring, Steven, Mujagic, Zlatan, Oostenbrug, Liekele, Romberg‐Camps, Mariëlle, Jonkers, Daisy, van Bodegraven, Adriaan, Pierik, Marieke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544244/ https://www.ncbi.nlm.nih.gov/pubmed/35794735 http://dx.doi.org/10.1111/apt.17128 |
Ejemplares similares
-
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
por: Kennedy, N A, et al.
Publicado: (2014) -
Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype
por: Broekman, M. M. T. J., et al.
Publicado: (2017) -
Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2023) -
Disease Activity Patterns of Crohn’s Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort
por: Wintjens, Dion, et al.
Publicado: (2020) -
Severe COVID-19 in inflammatory bowel disease patients in a population-based setting
por: Creemers, Rob H., et al.
Publicado: (2021)